

## OVERVIEW OF THE METABOLIC SYNDROME; AN EMERGING PANDEMIC OF PUBLIC HEALTH SIGNIFICANCE

A.O. Oladejo

Department of Internal Medicine, Federal Medical Center, Ido-Ekiti, Ekiti State, Nigeria

*Correspondence:*

**Dr. A.O Oladejo**

Department of Internal Medicine  
Federal Medical Center  
Ido-Ekiti  
Ekiti State, Nigeria.

### ABSTRACT

**A cluster of risk factors for cardiovascular disease and type 2 diabetes mellitus, which occur together have become known as the metabolic syndrome. Over the years various diagnostic criteria have been proposed by different organizations and most recently efforts have been made to unify the diagnostic criteria. This article is aimed at providing an overview of the metabolic syndrome and a rational approach to the management of this very important clinical syndrome.**

### INTRODUCTION AND HISTORICAL BACKGROUND

The concept of the metabolic syndrome has existed for at least 80 years<sup>1</sup>. It was first described by Kylin, a Swedish Physician, as the clustering of hypertension, hyperglycemia, and gout<sup>2</sup>. Later, in 1947, Vague drew attention to upper abdominal adiposity (android or male-type obesity) as the obesity phenotype that was commonly associated with type 2 diabetes mellitus and cardiovascular disease<sup>3</sup>.

The field moved forward significantly following the 1988 Banting lecture given by Gerald Reaven. He described a cluster of risk factors for diabetes and cardiovascular disease comprising hypertension, hyperglycemia, low high-density lipoprotein (HDL) cholesterol, and raised very low-density lipoprotein (VLDL) triglyceride and named it Syndrome X. His main contribution was the introduction of the concept of insulin resistance<sup>4</sup>.

The metabolic syndrome is also known as Syndrome X, the insulin resistance syndrome, cardio-metabolic syndrome, dysmetabolic syndrome and the deadly quartet syndrome<sup>5,6</sup>. The constellation include glucose intolerance (type 2 diabetes, impaired fasting glucose, or impaired glucose tolerance), insulin resistance, central obesity, dyslipidemia, and hypertension, all well documented risk factors for cardiovascular diseases. The metabolic syndrome is associated with an increased risk for the development of type 2 diabetes mellitus and cardiovascular disease. People with the syndrome are twice as likely to die from a macrovascular event and three times as likely to have ischemic heart disease and stroke compared with people without the syndrome<sup>7</sup>. The syndrome is affecting the general population in epidemic proportion and is frequently associated with increased risk of cardiovascular morbidity and mortality<sup>8,9</sup>.

### *Epidemiology*

Over the past two decades, a striking increase in the number of people with the metabolic syndrome worldwide has taken place. This increase is associated with the global epidemic of obesity and diabetes. With the elevated risk not only of diabetes but also of cardiovascular disease from the metabolic syndrome, there is an urgent need for strategies to prevent the emerging global epidemic<sup>10, 11</sup>.

In the United States, the metabolic syndrome is emerging as a major public health problem. Between 1988-1994 and 1999-2000, the age adjusted prevalence of the metabolic syndrome increased dramatically among women (23.5%) and only slightly among men (2.2%). An estimated 55 million adults in the United States had the syndrome in 2000. The age adjusted prevalence was 31.9% among Mexican Americans, 23.8% among non-Hispanic whites, and 21.6% among African Americans<sup>12,13</sup>.

The prevalence of the metabolic syndrome among a multi-ethnic population of 1276 men and women from four communities in Canada was 25.8%<sup>14</sup>. The prevalence in a population based cohort of 1565 individuals with diabetes in Italy was 75.6%<sup>15</sup>. A study done in Oman showed a prevalence of 23.0% in women and 19.5% in men<sup>16</sup>. The prevalence of the metabolic syndrome among healthy elderly South-western Nigerians was 35%<sup>17</sup> while a study done in Benin, Nigeria using three diagnostic tools - World Health Organization (WHO), Adult Treatment Panel (ATPIII) and International Diabetes Federation (IDF) criteria revealed a prevalence of 33.4%, 22.6% and 30.9% respectively<sup>18</sup>.

### Clinical Diagnosis of Metabolic Syndrome

Many investigations confirm that multiple cardiovascular risk factors of endogenous origin commonly aggregate in one individual. Although the metabolic syndrome is often referred to as a discrete entity, it is important to recognize it as a syndrome and not a defined uniform entity. No single pathogenesis has been elucidated but the syndrome could range from a cluster of unrelated risk factors to a constellation of risk factors linked through a common underlying mechanism.

In the effort to introduce the metabolic syndrome into clinical practice, several organizations have attempted to formulate simple criteria for its diagnosis. The first proposal came in 1998 from a consultation group on

the definition of diabetes for the World Health Organization. This group emphasized insulin resistance as the major underlying risk factor and required evidence of insulin resistance for diagnosis<sup>19</sup>.

In 1999, the European group for the Study of Insulin Resistance (EGIR) proposed a modification of the WHO definition. This group used the term insulin resistance syndrome rather than metabolic syndrome<sup>20</sup>. In 2001, the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP) introduced alternative clinical criteria for defining the metabolic syndrome. In so doing, the purpose of ATP III was to identify people at higher long-term risk for arterosclerotic vascular disease (ASCVD) who deserved clinical and lifestyle modification to reduce risk<sup>21</sup>.

Clinical measures	WHO (1998)	EGIR	ATP III (2001)	AACE(2003)	IDF(2005)	IDF/ATP III 2009
Insulin Resistance	IGT, IFG T2DM or lowered insulin sensitivity plus any two of the following	Plasma insulin > 75 <sup>th</sup> percentile plus any 2 of the following	None but any 3 of the following 5 features	IGT or IFG plus any of the following	None	None Any 3 of the following
Body Weight	Men; waist to hip ratio = 0.90. Women = 0.85 and or BMI = 30Kg/m <sup>2</sup>	WC= 94cm in men and 80cm in women	WC= 102cm in men or= 88cm in women	BMI= 25kg/m <sup>2</sup>	Increased WC (population specific) plus any 2 of the following	Increased WC (population specific)
Lipid	TG= 150mg/dl and/ or HDL-C= 35mg/dl in men and 39mg/dl in women.	TG=150mg/dl. HDL-C< 39mg/dl in men and women.	TG=150mg/dl. HDL-C < 40mg/dl in men and < 50mg/dl in women.	TG=150mg/dl and HDL-C < 40mg/dl in men or < 50mg/dl in women	TG=150mg/dl or on Rx. HDL-C <40mg/dl in men and <50mg/dl in women or on Rx.	Similar to IDF
Blood pressure	=140/90mmHg	=140/90	=130/85	=130/85	=130 or = 85 or on Rx	Similar to IDF
Glucose	IGT, IFG, T2DM	IGT, IFG (not diabetes)	FBG> 100mg/dl includes diabetes.	IGT or IFG but not diabetes	FBG> 100mg/dl including diabetes.	Similar to IDF
Others	Microalbuminuria			Other features of insulin resistance		

**Table 1:** Clinical diagnosis of metabolic syndrome

TG-Triglyceride HDL-C –High density lipoprotein IGT –Impaired glucose tolerance IFG- Impaired fasting glucose FBG – Fasting blood glucose T2 DM –Type 2 Diabetes Mellitus BMI- Body mass index Rx- Treatment

In 2003, the American Association of Clinical Endocrinologists (AACE) modified ATPIII criteria to focus on insulin resistance as the primary cause of the metabolic risk factors. Like the EGIR, the term insulin resistance syndrome was used<sup>22</sup>. In 2005, the International Diabetes Federation (IDF) published new criteria that again modified the ATPIII definition. The IDF writing group included several members of the original WHO consultation group. They liked the ATPIII criteria because of its clinical simplicity. They were of the opinion that abdominal obesity is highly

correlated with insulin resistance such that other more laborious measures of insulin resistance were unnecessary<sup>23</sup>. Most recently, efforts have been made to harmonize the criteria proposed by the ATPIII and the IDF consensus was that abdominal obesity should not be a prerequisite for diagnosis rather it should be one of the 5 criteria and the ethnic specific cut-off values as proposed by the IDF should be adopted<sup>24</sup>.

**Population Specific cut off points for waist circumference**

	Male	Female
Europeans	≥94cm	≥80cm
South Asians	≥90cm	≥80cm
Japanese	≥85cm	≥90cm
Sub-Sahara Africa	≥94cm	≥80cm

**Abnormal Body Fat**

- General body fat distribution
- Central fat distribution
- Liver fat content/ myocellular fat

**Atherogenic Dyslipidemia**

- ↑ Triglyceride
- ↓ HDL-C
- ↑ Small dense LDL particles

**Dysglycemia**

- IFG, IGT

**Insulin Resistance**

- ↑ Fasting insulin/pro-insulin
- Homeostatic model assessment for insulin resistance
- Elevated free fatty acids

**Vascular Dysregulation**

- Hypertension
- Measurement of endothelial dysfunction
- Microalbuminuria
- Chronic renal disease

**Pro-inflammatory States**

- ↑ High-sensitivity CRP
- ↑ inflammatory cytokines (IL-6)

**Prothrombotic States**

- Fibrinolytic factors (Plasminogen activator inhibitor)
- Clotting factors (fibrinogen)

**Others**

- Activation of the corticosteroid axis,
- polycystic ovarian syndrome
- Hyperuricemia, elevated asymmetric dimethylarginine
- Non-alcoholic fatty liver/steatohepatitis,
- obstructive sleep apnea

**Management of the Metabolic Syndrome**

The primary goal of clinical management in individuals with the metabolic syndrome is to reduce risk for arterosclerotic vascular disease. Even in people with the metabolic syndrome, first-line therapy is directed toward major risk factors: LDL-Cholesterol above the target goal, hypertension, and diabetes. Prevention of type 2 diabetes mellitus is another important goal when it is not present in a person with the metabolic syndrome. For individuals with established diabetes, risk factor management must be intensified to diminish their higher risk for arterosclerotic vascular disease. The prime emphasis in management of the metabolic syndrome is to mitigate the modifiable underlying risk factors (obesity, physical inactivity, and atherogenic diet) through lifestyle changes.

**Obesity and Physical Inactivity**

Weight reduction deserves first priority in individuals with obesity and the metabolic syndrome. Both weight reduction and maintenance of a lower weight are best achieved by a combination of reduced caloric diet, increased physical activity and the use of principle of behavioral change. Medications such as phentermine, orlistat, sibutamine, bupropion and rimonabant may also be of value in some patients when indicated. So also is bariatric surgery which is being used increasingly in the United States for severe obesity.

Increasing physical activity assists in weight reduction and reduces overall ASCVD risk. Current recommendations for the public call for accumulation of greater than 30 minutes of moderate-intensity exercise, such as brisk walking, on most, and preferably all days of the week. Preference is given to 60 minutes of moderate intensity brisk walking to be supplemented by other activities. These activities include use of treadmill, jogging, swimming, biking, golfing, team sports, and resistance training<sup>25-31</sup>.

**Atherogenic Dyslipidemia**

This condition consists of abnormal level of triglycerides and apoB, small LDL particles, and low HDL-Cholesterol. LDL-Cholesterol is the primary target for therapy while the other lipid abnormalities are secondary. LDL-C reduction goals depend on estimates of absolute risks as recommended by the

**Table 2:** Components of metabolic syndrome

ATPIII of the National Cholesterol Education Program. A related and potential secondary target is elevated total apoB, this measure denotes the number of atherogenic lipoprotein in the circulation. Statins lower both LDL-C and non-HDL-C by a similar percentage. Moreover statins reduce risk for ASCVD events in patients with the metabolic syndrome. Both fibrates and nicotinic acid reduce non-HDL-C and reportedly decrease the risk for ASCVD<sup>32-34</sup>.

#### *Systemic Hypertension*

When overt hypertension is present without diabetes or chronic kidney disease, the goal for antihypertensive therapy is a blood pressure of less than 140/90mmHg. In the presence of diabetes or chronic kidney disease, the blood pressure goal is less than 130/80mmHg. Mild elevations of blood pressure often can be effectively controlled with lifestyle therapies such as weight control, increased physical activity, alcohol moderation, sodium reduction, smoking cessation and increased consumption of fresh fruits, vegetables and low-fat dairy products. If hypertension cannot be adequately controlled by lifestyle therapies, antihypertensive drugs usually are necessary to prevent long-term adverse effects<sup>35</sup>. Some investigators support angiotensin-converting enzyme (ACE) inhibitors as first line therapy for hypertension in metabolic syndrome, especially when either type 2 diabetes mellitus or chronic kidney disease is present. Indeed inhibition of the rennin-angiotensin system with ACE inhibitors or Angiotensin receptor blocker (ARBs) may lower risk for diabetes itself<sup>36</sup>. The results of a large clinical trial raised the possibility that use of diuretics in patients with impaired fasting glucose or impaired glucose tolerance may increase the likelihood of progression to type 2 diabetes mellitus, although diuretics do in fact lower the risk for cardiovascular events. Most investigators in the hypertension field believe that the potential benefit of low dose diuretics in combination antihypertensive therapy outweighs their risk especially in blacks<sup>37</sup>.

#### *Insulin Resistance and Hyperglycemia*

Lifestyle intervention can reduce the risk for conversion of impaired fasting glucose (IFG) and impaired glucose tolerance (IGT) to type 2 diabetes. Preliminary reports indicate that metformin, thiazolidinediones or acarbose also reduce risk of type 2 diabetes in people with IFG or IGT<sup>38, 39</sup>.

Glycemic control to a hemoglobin A1c of less than 7% will reduce microvascular complications and could reduce the risk for macrovascular disease as well. The use of lipid-altering, anti-hypertensive and anti-diabetic drugs can modify insulin sensitivity and body weight. Metformin and thiazolidinediones improve insulin

sensitivity but have discrepant effects on body weight: metformin reduces weight while thiazolidinediones increase it<sup>40</sup>.

#### *Prothrombotic State*

This risk factor is characterized by elevations of fibrinogen, plasminogen activator inhibitor 1, and possibly other coagulation factors. The only available clinical approach to reducing an increased risk for arterial thrombosis in patients with diabetes is to give anti-platelet drugs. These drugs are universally recommended unless contraindicated in patients with established cardiovascular disease. In other people with the metabolic syndrome, aspirin prophylaxis is a therapeutic option when the risk for cardiovascular disease events is judged to be relatively high<sup>41, 42</sup>.

#### *Pro-inflammatory State*

This condition can be identified by elevated cytokines (TNF $\alpha$  and interleukin 6) and acute phase reactants (C-reactive protein and fibrinogen). An elevated C-reactive protein is widely thought to be an indicator of a pro-inflammatory state and to be associated with higher risk for both cardiovascular disease and diabetes. Lifestyle therapies especially weight reduction, will reduce concentrations of this cytokine and thus mitigate an underlying inflammatory state. No specific anti-inflammatory drugs are available to treat this state. However, several drugs used to treat other metabolic risk-factors- statins, fibrates, and thiazolidinediones- have been reported to reduce concentrations of C-reactive proteins<sup>43, 44</sup>.

## **CONCLUSION**

Metabolic syndrome represents a constellation of cardiovascular risk factors which increase the risk of arterosclerotic cardiovascular disease and development of type 2 diabetes. Type 2 diabetes poses a major public health problem world-wide with a projected number of over 300 million people by 2025. Risk stratification, early identification and radical intervention will thus help in stemming the tide of this dangerous trend.

## **REFERENCES**

1. **Cameron AJ**, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in world-wide populations. *Endocrinol Metab Clin North Am* 2004; 33: 351-75.
2. **Kylin E**. Studien. Hypertonie-Hyperglykämie-Hyperurikämiesyndrome. *Zentralblatt für innere Medizin* (44). 1923.
3. **Vague J**. La différenciation sexuelle, facteur déterminant des formes de l'obésité. *Presse Med.* 1947; 30: 339-340.

4. **Reaven GM.** Banting lecture 1988. Role of insulin resistance in human disease. *Diabetes* 1988; 37: 1595-1607.
5. **DeFronzo RA,** Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and arterosclerotic cardiovascular disease. *Diabetes Care* 1991; 14: 173-194.
6. **Kaplan NM.** The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. *Arch Intern Med* 1989; 149: 1514-1520.
7. **Ninmuja JK,** L'Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. *Circulation* 2004; 109: 42-46.
8. **Isomaa B,** Almgren P, Tuomi T. Cardiovascular morbidity and mortality associated with the metabolic syndrome. *Diabetes Care* 2001; 24: 683-689.
9. **Lakka HM,** Laaksonen DE, Lakka TA. The metabolic syndrome and total cardiovascular disease mortality in middle-aged men. *JAMA* 2002; 288: 2709-2716.
10. **Zimmet P,** Alberti KG, Shaw J. Global and societal implications of diabetes epidemic. *Nature* 2001; 414: 782-787.
11. **Grundey SM,** Hansen B, Smith SC, Jr, Cleeman JI, Kahn RA. Clinical management of metabolic syndrome: report of the American Heart Association/ National Heart, Lung, and Blood Institute/ American Diabetes Association conference on scientific issues related to management. *Circulation* 2004; 109: 551-556.
12. **Ford ES,** Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among US adults. *Diabetes Care* 2004; 27: 2444-2449.
13. **Ford ES,** Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: finding from the third National Health and Nutrition Examination Survey. *JAMA* 2002; 287: 356-359.
14. **Anand SS,** Yi Q, Gerstein H. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. *Circulation* 2003; 108: 420-425.
15. **Bruno G,** Merletti F, Biggeri A. Metabolic syndrome as a predictor of all cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. *Diabetes Care.* 2004; 27: 2689-2694.
16. **Al-Lawati JA,** Mohammed AJ, Al-Hinai HQ. Prevalence of the metabolic syndrome among Omani adults. *Diabetes Care* 2003; 26: 1781-1785.
17. **Ezenwaka CE,** Akanji AO, Akanji BO, Unwin NC, Adejuwon CA. The prevalence of insulin resistance and other cardiovascular disease risk factors in healthy elderly southwestern Nigerians. *Atherosclerosis* 1997; 128 (2): 201-211.
18. **Eregie A,** Edo A. Diagnosing the metabolic syndrome: a comparative evaluation of three diagnostic tools. *Diabetes Medicine* 2006. Dec; 23(Suppl.4), P2107.
19. **Alberti KG,** Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complication, part1; diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabetes Medicine.* 1998; 15: 539-553.
20. **Balkau B,** Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance. *Diabetes Medicine* 1999; 16: 442-443.
21. **Clinical Guidelines on the identification, Evaluation, and treatment of Overweight and obesity in Adults- the Evidence Report.** National Institute of Health. *Obes Res* 1998; (Suppl 2): 51-209.
22. **Einhorn D,** Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y, Hellman R *et al.* American College of Endocrinology position statement on the insulin resistance syndrome. *Endocr Pract.* 2003; 9:237-252.
23. **International Diabetes Federation Worldwide definition of the metabolic syndrome.** Available at [http://www.idf.org/webdata/docs/IDF\\_Meta-syndrome\\_definition.pdf](http://www.idf.org/webdata/docs/IDF_Meta-syndrome_definition.pdf) August 2005.
24. **Alberti KG,** Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI *et al.* Harmonizing the Metabolic Syndrome. A joint interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerotic Society; and International Association for the Study of Obesity. *Circulation* 2009; 120: 1640-1645.
25. **Klein S,** Burke LE, Bray GA, Blair S *et al.* American Heart Association Council on Nutrition, Physical Activity, and Metabolism; American College of Cardiology Foundation. Clinical implications of obesity with specific focus on cardiovascular disease. *Circulation* 2004; 110: 2952-2967.
26. **Bray GA,** Greenway FL. Current and potential drugs for treatment of obesity. *Endocrine Rev* 1999; 20: 805-875.
27. **Balsinger BM,** Mirr MM, Poggio JL, Sarr MG. Bariatric surgery. Surgery for weight control in

- patients with morbid obesity. *Med Clin North Am* 2000; 84: 477-489.
28. **Frankin BA**, Kahn JK, Gordon NF, Bonow RO. A cardioprotective polypill? Independent and additive benefits of lifestyle modification. *Am J Cardiol* 2004;109: 551-556.
  29. **Grundy SM**, Hansen B, Smith SC Jr, Cleeman JI, Kahn RA. American Heart Association; National Heart, Lung, and Blood Institute; American Diabetes Association. Clinical management of metabolic syndrome. *Circulation* 2004; 109: 551-556.
  30. **Thompson PD**, Buchner D, Pina II, Balady GJ *et al.* American Heart Association Council on Clinical Cardiology. Subcommittee on Exercise, Rehabilitation, and prevention. *Circulation* 2003; 107:3109-3116.
  31. **Pollock ML**, Franklin BA, Balady GJ *et al.* Resistance exercise in individuals with and without cardiovascular disease: benefits, rationale, safety, and prescription: an advisory from the Committee on Exercise, Rehabilitation, Prevention, Council on Clinical Cardiology, American College of Sports Medicine. *Circulation* 2000; 101: 828-833.
  32. **Ballantyne CM**, Olsson AG, Cook TJ, Mercuri MF *et al.* Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. *Circulation* 2001; 104: 3046-3051.
  33. **Rubin HB**. Triglycerides and coronary heart disease: implications of recent clinical trials. *J Cardiovasc Risk* 2000; 7: 339-345.
  34. **Rubins HB**, Robins SJ, Collins D, Nelson DB *et al.* Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial. *Arch Intern Med* 2002; 162: 2597-2604.
  35. **Chobanian AV**, Bakris GL, Black HR *et al.* National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood pressure. *JAMA* 2003; 289: 2560-2572.
  36. **Barnet AH**, Bain SC, Bouter P *et al.* Diabetics exposed to Telmisartan and Enalapril Study Group. Angiotensin-receptor blockade versus converting enzyme inhibition in type 2 diabetes and nephropathy. *N Engl J Med* 2004; 351: 1952-1961.
  37. The ALLHAT Officers and Coordinator for the ALLHAT Collaborative Research Group; The Antihypertensive and Lipid-lowering Treatment to prevent Heart Attack Trial. Major outcomes in high risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretics. *JAMA* 2002; 288: 2981-2997.
  38. **Knowler WC**, Barret-Connor E, Fowler SE. Reduction in the incidence of type 2 diabetes with life style intervention of metformin. *N Engl J Med* 2002; 346: 393-403.
  39. **Zimmet P**, Shaw J, Alberti KG. Preventing Type 2 diabetes and dysmetabolic syndrome in the real world.: a realistic view. *Diabetes Medicine* 2003; 20: 693-702.
  40. **Buchanan TA**, Xiang AH, Peters RK. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high risk Hispanic women. *Diabetes* 2002; 51: 2796-2803.
  41. **Colwell JA**. Anti-platelet agents for the prevention of cardiovascular disease in diabetes mellitus. *Am J Med* 2003; 115(Suppl 8A): 42-48.
  42. **Pearson TA**, Blair SN, Daniels SR. AHA Guidelines for primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adults Patients without Coronary or other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. *Circulation* 2002; 106: 388-391.
  43. **Jialal I**, Stien D, Balis D, Grundy SM *et al.* Effects of hydroxymethyl glutaryl coenzyme A reductase inhibitor therapy on high sensitive C reactive protein levels. *Circulation* 2001; 103: 1933-1935.
  44. **Nesto R**. C-reactive protein, its role in inflammation, type 2 diabetes and cardiovascular disease, and effect of insulin sensitizing treatment with thiazolidinediones. *Diabetes Medicine* 2004; 21: 810-817.